India's Pharma Barons Are Reporting Delays in Digitizing Labs
- Underestimated scale, complexity of the job, Sun Pharma says
- India supplies 40% of generic drugs to the U.S. market
This article is for subscribers only.
Heads of two of India’s largest drug makers said integration of electronic systems to prevent quality lapses in factories is going slower than expected, as the industry looks to adapt to increased scrutiny from regulators in the developed world that have resulted in sanctions and slowed sales.
"This is a much more digital world than where pharma companies are and definitely where generic companies are," Nilesh Gupta, managing director of Lupin Ltd., India’s second most valuable pharmaceutical company, said at the the Indian Pharmaceutical Forum in Mumbai. "I think we should use technology and data a lot more."